Agents and Actions

, Volume 37, Issue 3–4, pp 260–267 | Cite as

Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester

  • J. G. Alford
  • P. L. Stanley
  • G. Todderud
  • K. M. Tramposch
Inflammation and Immunomodulation


We have previously shown that multiple topical applications, over 11 days, of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces a persistent inflammatory reaction characterized by edema, cell infiltration and epidermal hyperplasia. In order to characterize the cell infiltrate during the establishment of this inflammatory reaction, immunohistochemistry was performed using two monoclonal antibodies: MOMA-2, a macrophage antibody and Thy-1, a pan T-cell antibody. The level of polymorphonuclear leukocytes (PMNs) peaked by day 3 at 160-fold over nontreated controls and then subsided to a 30-fold elevation on days 7–10. By day 4, the number of macrophages increased 2.9-fold over the nontreated control and by day 10 were elevated 6.0-fold over the nontreated control. In comparison, the number of T-cells present by day 7 was significantly elevated 9.5-fold over the nontreated group and peaked at day 8 with a 19-fold elevation relative to nontreated controls. Topical treatment of animals with hydrocortisone valerate resulted in a dramatic (>60%) reduction in the number of T-cells present in the tissue. In contrast, there was no effect of the steroid on the number of macrophages present in the tissue. The identification of specific cell types and their time course of infiltration is consistent with the development of a chronic inflammatory lesion.


Hydrocortisone Valerate Inflammatory Reaction Phorbol Ester Inflammatory Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    L. M. De Young, J. B. Kheifets, s. J. Ballaron and J. M. Young,Edema and cell infiltration in the phorbol estertreated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. Agents and Actions26, 335–341 (1989).PubMedGoogle Scholar
  2. [2]
    R. P. Carlson, L. O'Neill-Davis, J. Chang and A. J. Lewis,Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents and Actions17, 197–204 (1985).PubMedGoogle Scholar
  3. [3]
    P. L. Stanley, S. Steiner, M. Havens and K. M. Tramposch,Mouse skin inflammation induced by multiple topical applications of 12-o-tetradecanoylphorbol-13-acetate. Skin Pharmacol.4, 262–271 (1991).PubMedGoogle Scholar
  4. [4]
    A. Lassus and S. Forsstrom,A dimethoxynapthalene derivative (RS-43179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis. Br. J. Dermatol.113, 103–106 (1985).PubMedGoogle Scholar
  5. [5]
    C. A. Green and S. Shuster,Lack of effect of topical indomethacin on psoriasis. Br. J. Clin. Pharmacol.24, 381–384 (1987).PubMedGoogle Scholar
  6. [6]
    H. Katayama and A. Kawada,Exacerbation of psoriasis induced by indomethacin. J. Dermatol.8, 323–327 (1981).PubMedGoogle Scholar
  7. [7]
    A. D. Sedgewick and D. A. Willoughby,Initiation of the inflammatory response and its prevention. InThe Handbook of Inflammation. The pharmacology of Inflammation, vol. 5, (Ed. I. L. Bonta, M. A. Bray and M. J. Parnham) pp. 27–47, Elsevier, New York 1985.Google Scholar
  8. [8]
    P. P. Bradley, D. A. Priebat, R. D. Christensen and G. Rothstein,Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol.78, 206–209 (1982).PubMedGoogle Scholar
  9. [9]
    G. Kraal, M. Rep and M. Janse,Macrophages in T and B cell compartments and other tissue macrophages recognized by monoclonal antibody MOMA-2: An immunohistochemical study. Scand. J. Immunol.26, 653–661 (1987).PubMedGoogle Scholar
  10. [10]
    P. Lake, E. A. Clark, M. Khorshidi and G. H. Sunshine,Production and characterization of cytotoxic Thy-1 antibody-secreting hybrid cell lines. Detection of T cell subsets. Eur. J. Immunol.9, 875–876 (1979).PubMedGoogle Scholar
  11. [11]
    J. A. Ledbetter and L. A. Herzenberg,Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev.47, 63–90 (1979).PubMedGoogle Scholar
  12. [12]
    T. Aoki, U. Hammerling, E. De Harven, E. A. Boyse and L. J. Old,Antigenic structure of cell surfaces. An immunoferrutin study of the occurrence and topography of H-2, Theta and TL alloantigens on mouse cells. J. Exp. Med.130, 979–1001 (1969).PubMedGoogle Scholar
  13. [13]
    M. C. Raff,Surface antigenic markers for distinguishing T and B lymphocytes in mice. Transplant Rev.6, 52–80 (1971).PubMedGoogle Scholar
  14. [14]
    G. Fuerstenberger and F. Marks,Early prostaglandin E synthesis is an obligatory event in the induction of cell proliferation in mouse epidermis in vivo by the phorbol ester TPA. Biochem Biophys. Res. Commun.92, 749–756 (1980).PubMedGoogle Scholar
  15. [15]
    C. M. Aldaz, C. J. Conti, I. B. Gimenez, T. J. Slaga and A. J. P. Klein-Szanto,Cutaneous changes during prolonged application of 12-o-tetradecanoylphorbol-13-acetate on mouse skin and residual effects after cessation of treatment. Cancer Res.45, 2753–2759 (1985).PubMedGoogle Scholar
  16. [16]
    W. Aberer, L. Stingl, S. Pogantsch and G. Stingl,Effect of glucocorticosteroids on epidermal cell-induced immune responses. J. Immunol.133, 792–797 (1984).PubMedGoogle Scholar
  17. [17]
    K. M. Tramposch, F. C. Zusi, S. A. Marathe, P. L. Stanley, X. Nair, S. A. Steiner and J. W. Quigley,Biochemical and pharmacological properties of a new topical anti-iflammatory compound, 9-phenylnonanohyroxamic acid (BMY 30094). Agents and Actions30, 443–450 (1990).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1992

Authors and Affiliations

  • J. G. Alford
    • 1
  • P. L. Stanley
    • 1
  • G. Todderud
    • 1
  • K. M. Tramposch
    • 1
  1. 1.Dermatology Discovery ResearchBristol-Meyers Squibb Pharmaceutical Research InstituteBuffaloUSA

Personalised recommendations